BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a market perform rating and a $107.00 price target on the biotechnology company's stock.

BMRN has been the topic of several other reports. StockNews.com assumed coverage on BioMarin Pharmaceutical in a report on Wednesday, October 12th. They set a buy rating on the stock. Morgan Stanley raised their price target on shares of BioMarin Pharmaceutical from $113.00 to $132.00 and gave the company an overweight rating in a report on Tuesday, January 24th. Evercore ISI boosted their price objective on shares of BioMarin Pharmaceutical to $130.00 in a report on Friday, December 2nd. Guggenheim raised their target price on BioMarin Pharmaceutical from $120.00 to $125.00 in a research note on Monday, January 9th. Finally, Canaccord Genuity Group began coverage on BioMarin Pharmaceutical in a research report on Wednesday, January 18th. They set a hold rating and a $119.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $119.39.

BioMarin Pharmaceutical Stock Down 2.2 %

Shares of BioMarin Pharmaceutical stock opened at $114.70 on Monday. BioMarin Pharmaceutical has a twelve month low of $70.73 and a twelve month high of $117.77. The stock has a market cap of $21.27 billion, a price-to-earnings ratio of 274.00 and a beta of 0.36. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24. The company has a fifty day moving average price of $105.75 and a 200 day moving average price of $94.50.

Insider Activity

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Altshuler Shaham Ltd bought a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at about $25,000. Quadrant Capital Group LLC raised its position in shares of BioMarin Pharmaceutical by 188.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company's stock worth $29,000 after buying an additional 232 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 344 shares during the period. Capital Wealth Alliance LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $34,000. Finally, Baystate Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $41,000. Institutional investors own 96.26% of the company's stock.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Further Reading

• Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.